Condition
HR Positive/HER-2 Negative Breast Cancer
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Not Yet Recruiting2
Recruiting1
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07383506Phase 1Not Yet Recruiting
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07211178Recruiting
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
NCT07102940Phase 2Not Yet Recruiting
Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer
NCT06172322Phase 1UnknownPrimary
A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer
Showing all 4 trials